Exelixis CSO Identifies Genomics Mortal Sin and Rustles Up Some Remedies | GenomeWeb

SAN FRANCISCO, June 24 - As genomics struggles through biotech's recent hardships, "drug development" is quickly emerging as the most-favorable business for companies originally built for selling tools and technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.